Current trends in novel drug delivery - An OTC perspective

Pharma Times

Volumn 42, Issue 4, 2010, Pages 17-23

  Nadkar, Sumedha ^a   Lokhande, Chandrakant ^a  

^a NOVARTIS HEALTHCARE PVT LTD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUORO 1,3 DIHYDRO 2,1 BENZOXABOROL 1 OL; BUTOCONAZOLE; CLOTRIMAZOLE; DEISYM; DIMENHYDRINATE; FLUOROURACIL; LIPOSOME; MICONAZOLE; NANOSTRUCURED LIPID CARRIER; NON PRESCRIPTION DRUG; PECTIN; SOLID LIPID NANOPARTICLE; TIOCONAZOLE; UNCLASSIFIED DRUG;

ACNE; BIOMEDICAL ENGINEERING; BIOTECHNOLOGY; CLINICAL EVALUATION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG FORMULATION; DRUG LEGISLATION; ION EXCHANGE; MICROEMULSION; MICROSPONGE DELIVERY SYSTEM; NANOTECHNOLOGY; ONYCHOMYCOSIS; ORAL STRIP TECHNOLOGY; ORALLY DISINTEGRATING TABLET; OSMOSIS; REVIEW; RISK BENEFIT ANALYSIS; SELF MICRO EMULSIFYING DRUG DELIVERY SYSTEM; TABLET FORMULATION; VAGINAL DRYNESS;

EID: 78549256470     PISSN: 00316849     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. The Pharmaceutical OTC Outlook to 2010 by Kate Bradley, http://www.globalbusinessinsights.com/content/rbhc0007m.pdf
2. http://www.fda.gov/cder/otc/index.htm
3. http://www.fda.gov/cder/otcmonographs/rulemaking-index.htm
4. Blume; R.W., Davis, R. D. and Keyser; D. J.,Guaifenesin sustained release formulation and tablets, 2002,US patent 6,372,252.
5. Dey,N.S., Majumdar,S. and Rao, M.E.B., Multiparticulate Drug Delivery Systems for Controlled Release, Tropical Journal of Pharmaceutical Research, 2008, 7 (3): 1067-1075.
6. http://www.prevacid24hr.com
7. http://www.pharmainfo.net/reviews/drug-delivery-and-therapeutic- applications-ion-exchange-resins-update
8. Cherukuri, S. R., et al, Medicated chewing gum delivery system for nicotine,2002, United States Patent 6344222
9. Sayed, U.G. and Bajaj, A.N. ,Oral controlled release bromhexine ion-exchange resinate suspension formulation. Indian Drugs, 2000,37, 185-189.
10. M. Cuña, M. J. Alonso and D. Torres, Preparation and in vivo evaluation of mucoadhesive microparticles containing amoxycillin-resin complexes for drug delivery to the gastric mucosa, Eur. J. of Pharm.and Biopharm., 2001,51(3,) 199-205.
11. Amin,P., Prabhu,N., Wadhwani,A., Indion 414 as superdisintegrant in formulation of mouth dissolve tablets, Ind. J. Pharm. Sci.,2006, 68(1), 117-119.
12. http://www.rohmhaas.com/assets/attachments/business/Rocess-chemicals/ amberlite-and-duolite-Pharmaceutical-grade-resins/New-Uses-of-Ion-Exchange- Resins-n-Pharmaceutical-Formulations.pdf
13. Eichman; M.L Drug-resin complexes stabilized by chelating agents, US patent 5,980,882, 1999,
14. http://www.drugs.com/cdi/claritin-reditabs-orally-disintegrating-tablets . html
15. Hirani,J.J., Dhaval A., Rathod,D.A and Kantilal R Vadalia,K.L., Orally Disintegrating Tablets: A Review, Tropical Journal of Pharmaceutical Research, 2009; 8 (2): 161-172.
16. Dixit R.P. and Puthli, S.P., Oral strip technology: Overview and future potential, Journal of Controlled Release, 2009, 139, 94-107.
17. S P Vyas, R K Khar, Targeted and Controlled Drug Delivery-Novel Carrier System: New Delhi: CBS Publication, First edition; 2002:453
18. Cevc,G., Transferosomes,liposomes and other lipid suspensions on skin,permeation enhancement,vesicle penetration and transdermal drug delivery, Crit.Rev. Ther.,Drug Carrier Syst. 1996,13,257-388.
19. Attwood D. Microemulsions in Colloidal drug delivery systems (J. Kreuter ed.), Marcel Dekker, New York 1994
20. Grazieila ,L.M., Microemulsion & submicron emulsion process & compositions, WO/2006/024095, 2006.
21. http://www.vetcontact.com/presentations/midler1/abstracts/midler.pdf
22. Jadhav, K. R.; Ambade, K. W.; Jadhav, S. L.; Gambhire, M. N.; Kurmi, S. D.; Kadam, V. J., Formulation and Evaluation of Flurbiprofen Microemulsion, Current Drug Delivery, 2008, 5(1), 32-41.
23. Chandra, A., Sharma,P.K., Irchhaiya ,R., Microemulsion-based hydrogel formulation for transdermal delivery of dexamethasone, Asian Journal of Pharm., 2009 ,3(1), 30-36.
24. Mezei, M. and Gulasekharam, V. Liposomes:a selective drug delivery system for the topical route of administration. Lotion dosage form, Life Sci ,1980 ; 26 : 1473-7.
25. Castro G.A.,Ferreira,A.M,. Novel vesicular and particulate drug delivery systems for topical treatment of acne, Expert Opin.Drug Deliv ,2008,5(6),665-669.
26. Loy, G. and Fadda,A.M., Niosomes as carriers for tretinoin I Preparations and properties, Int. J. Pharm., 2002, 234,1-2237-248.
27. Skalko, N, Cajkovac, M., Jalenjack, I. Liposomes with clindamycin hydrochloride in the therapy of acne vulgaris. Int J Pharm ,1992 ; 85 : 97-101.
28. Bhalerao, S.S., Raje, H. Preparation, optimization, characterization and stability studies of salicylic acid liposomes, Drug Dev Ind Pharm, 2003 ; 29 : 451-67.
29. Shalita, A.R., Chalker, D.K., Griffith R.F., Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-bind, vehicle-controlled study, Cutis ,1999 ; 63 : 349-54.
30. http://www.gattefossecanada.ca/en/products/pharmaceutical/ bioavail-enhancers.shtml
31. Farah N. et al, Orally administrable composition capable of providing enhanced bioavailability when ingested, United States Patent 6312704, 2001.
32. Date, A.A., Naik, B., Nagarsenker, Novel drug delivery systems: potential in improving topical delivery of antiacne agents, Skin Pharmacol Physiol ,2006 ; 19 : 2-16.
33. Dingler,A., Gohla. S., Production of solid lipid nanoparticles (SLN): scaling up feasibilities, J Microencapsul, 2002 ; 19 : 11-6.
34. Müller, R.H., Karsten, M., Gohla, S., Solid lipid nanoparticles (SLN) for controlled drug delivery: a review of the state of the art, Eur J Pharm Biopharm 2000 ; 50 : 161-77.
35. Mehnert, W., Mäder, K., Solid lipid nanoparticles production, characterization and applications, Adv Drug Deliv Rev, 2001 ; 47 : 165-96.
36. Akman, A., Durusoy, C., Senturk, M., Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study. Arch Dermatol Res, 2007 ; 299 : 467-73.
37. Liu, J., Hu, W., Chen ,H, et al. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery, Int J Pharm, 2007 ; 328 : 191-5.
38. Doktorovova, S., Arajo, J. Garcia ,M .L., Rakovsky, Souto,E. B., "Formulating Fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC), Colloids and Surfaces B: Biointerfaces,75(2010),538- 542.
39. C omog lu, T, Go nu N., Microsponge delivery systems. J. Faculty of Pharm. Ankara Univ.; 2007, 29: 75-86.
40. Chadawar.V and Shaji, J., Microsponge delivery system, Current Drug Deliv, 2007,,4(2),123-9.
41. Jelvehgari,N., Siahi Shabad,M.R., Azarm, S., Martin, G, P.,Nakhodchi, A., The microsponge delivery system of benzoyl peroxide: Preparation, characterization and release studies, Int. J.Pharm., 2006,308(1,2),124-132.
42. Nakhodchi,A, Jelvehgari, M, Siahi, M.R and Mozafari, M, Factors affecting the morphology of benzoyl peroxide microsponges,, 2007, Micron ,38(8),834-40.
43. http://www.carac.info/hcp/microsponge.aspx
44. Belgamwar,V.S.,.Chauk,D.S., Mahajan,H.S., Jain,S.A, Gattani,S.G. and Surana,S.J, Formulation and evaluation of in situ gelling system of dimenhydrinate for nasal administration, Pharm. Dev. and Tech., 2009; 14(3): 240-248.
45. Pisal, S.S., Paradkar,A.R., Mahadik, K.R., Kadam, S.S.,Pluronic gels for nasal delivery of Vitamin B12. Part I: preformulation study, Int J Pharm., 2004 .270(1-2):37-45.
46. Dumortier, G., Grossiord, J.L. Agnely, F., Chaumeil, J.C., A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res, 2006 ,23(12):2709-28.
47. Cheng, Y., Watts,P., Hinchcliffe,M., Hotchkiss, P., Nankervis,R., Smith,F.A., Davis, S.S and Illum, L., Development of a novel nasal nicotine formulation comprising an optimal pulsatile and sustained plasma nicotine profile for smoking cessation, J. Controlled Release, 2002, 79, 243-254.
48. Lisa Brannon-Peppas, Novel vaginal drug release applications, Adv. Drug. Del. Rev., 1993,11(1-2), 169-177.
49. Digenis ,G.A., Nosek,D., Mohammadi,F., Darwazeh,N.B, Anwar,H.S, and Zavos,P.M., Novel vaginal controlled delivery systems incorporating coprecipitates of Nonoxynol-9, Pharm dev & tech ,1999, 4(3),421-430.
50. Mashru, R., Dobaria,N., Badhan, A., A Novel Itraconazole Bioadhesive Film for Vaginal Delivery: Design, Optimization, and Physicodynamic Characterization, 2009, AAPS Pharm. Sci.Tech,, 10(3), 951-959.
51. Esra ,B., Mine, O.,Yaprak, H.S., Taner, S., Dogan, O., Cetin, P., Bioadhesive controlled release systems of ornidazole for vaginal delivery, Pharm.dev.and tech., 2006, 11(4), 477-484.
52. Vermani,K. and Garg,S., The scope and potential of vaginal drug delivery Pharmaceutical Science & Technology Today, 2000,3(10), 1, 359-364.
53. J. das Neves and Bahiaa, M.F. ,Gels as vaginal drug delivery systems, 2006, Int. J.of Pharm.,318, (1-2), 1-14.
54. Over The Counter Products To Treat Vaginal Dryness LIVESTRONG-COM.htm
55. Tom, C.M., Kane, M.P., 1999. Management of toenail onychomycosis, Am. J. Health Syst. Pharm. 56, 865-871.
56. Elkeeba,R., AliKhanb,A., Elkeebc,L., Huia,X., Howard I. Maibacha, Transungual drug delivery: Current status, Int.J.of Pharm., 384 (2010) 1-8
57. Susilo, R., Korting, H.C., Greb, W., Strauss, U.P. Nail penetration of sertaconazole with a sertaconazole-containing nail patch formulation.., 2006, Am. J. Clin.Dermatol.,7, 259-262.
58. Hui,X., Baker, et al,2007,In vitro penetration of a novel Oxaborole antifungal (AN2690) into the human nail plate., J.Pharm..Sci, 96,2622-2631.
59. Jan,S., Bora, D., Bhise ,K., Preungual drug delivery systems of Terbenafine Hydrochloride Nail lacquer, Asian J. of Pharm., 2008, 53-56.